Humankind Investments LLC Purchases 985 Shares of Eli Lilly and Company (NYSE:LLY)

Humankind Investments LLC increased its holdings in Eli Lilly and Company (NYSE:LLY) by 29.1% in the 4th quarter, HoldingsChannel.com reports. The fund owned 4,368 shares of the company’s stock after buying an additional 985 shares during the period. Eli Lilly and Company comprises about 0.9% of Humankind Investments LLC’s holdings, making the stock its 17th biggest position. Humankind Investments LLC’s holdings in Eli Lilly and Company were worth $3,372,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors and hedge funds also recently modified their holdings of LLY. Guardian Wealth Advisors LLC NC boosted its stake in Eli Lilly and Company by 1.3% in the fourth quarter. Guardian Wealth Advisors LLC NC now owns 4,782 shares of the company’s stock valued at $3,692,000 after acquiring an additional 63 shares during the last quarter. Ground Swell Capital LLC lifted its stake in Eli Lilly and Company by 17.7% in the fourth quarter. Ground Swell Capital LLC now owns 345 shares of the company’s stock valued at $266,000 after purchasing an additional 52 shares during the last quarter. Francis Financial Inc. grew its holdings in Eli Lilly and Company by 60.0% during the fourth quarter. Francis Financial Inc. now owns 888 shares of the company’s stock valued at $686,000 after purchasing an additional 333 shares during the period. Full Sail Capital LLC increased its position in Eli Lilly and Company by 3.7% in the fourth quarter. Full Sail Capital LLC now owns 1,605 shares of the company’s stock worth $1,239,000 after buying an additional 57 shares during the last quarter. Finally, Ensign Peak Advisors Inc raised its stake in shares of Eli Lilly and Company by 0.3% in the fourth quarter. Ensign Peak Advisors Inc now owns 879,138 shares of the company’s stock valued at $678,695,000 after buying an additional 2,726 shares during the period. 82.53% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at Eli Lilly and Company

In related news, CAO Donald A. Zakrowski sold 1,000 shares of Eli Lilly and Company stock in a transaction on Thursday, March 13th. The shares were sold at an average price of $818.24, for a total value of $818,240.00. Following the transaction, the chief accounting officer now directly owns 5,840 shares of the company’s stock, valued at $4,778,521.60. The trade was a 14.62 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Company insiders own 0.14% of the company’s stock.

Analysts Set New Price Targets

Several brokerages recently weighed in on LLY. StockNews.com raised Eli Lilly and Company from a “hold” rating to a “buy” rating in a report on Friday, February 7th. UBS Group reduced their target price on shares of Eli Lilly and Company from $1,100.00 to $1,050.00 and set a “buy” rating for the company in a research note on Friday, May 2nd. Guggenheim restated a “buy” rating on shares of Eli Lilly and Company in a research note on Thursday, May 1st. Hsbc Global Res cut shares of Eli Lilly and Company from a “strong-buy” rating to a “moderate sell” rating in a report on Monday, April 28th. Finally, Truist Financial increased their target price on Eli Lilly and Company from $1,029.00 to $1,038.00 and gave the stock a “buy” rating in a research report on Monday, February 3rd. One analyst has rated the stock with a sell rating, two have assigned a hold rating and nineteen have assigned a buy rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $1,002.80.

Eli Lilly and Company Trading Down 2.0 %

NYSE LLY opened at $736.21 on Friday. The stock’s 50-day simple moving average is $810.98 and its two-hundred day simple moving average is $810.88. Eli Lilly and Company has a twelve month low of $677.09 and a twelve month high of $972.53. The company has a quick ratio of 0.97, a current ratio of 1.15 and a debt-to-equity ratio of 2.00. The company has a market capitalization of $697.73 billion, a price-to-earnings ratio of 62.87, a PEG ratio of 1.40 and a beta of 0.48.

Eli Lilly and Company (NYSE:LLY) last released its earnings results on Thursday, May 1st. The company reported $3.34 earnings per share for the quarter, missing analysts’ consensus estimates of $4.64 by ($1.30). The firm had revenue of $12.73 billion during the quarter, compared to the consensus estimate of $12.77 billion. Eli Lilly and Company had a return on equity of 85.24% and a net margin of 23.51%. The business’s quarterly revenue was up 45.2% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $2.58 EPS. Research analysts forecast that Eli Lilly and Company will post 23.48 EPS for the current fiscal year.

Eli Lilly and Company Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, June 10th. Investors of record on Friday, May 16th will be given a $1.50 dividend. This represents a $6.00 dividend on an annualized basis and a yield of 0.81%. The ex-dividend date is Friday, May 16th. Eli Lilly and Company’s payout ratio is presently 48.82%.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.